Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
PETALUMA, Calif., Feb. 05, 2016 -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that Jim Schutz, chief executive officer, and Bob Miller, chief financial officer, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference to be held at the Convene Conference Center, 730 Third Avenue, New York City on Wednesday, February 10, 2016 at 9:30am ET. Management will also be meeting with investors throughout the day.
About Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.oculusis.com.
Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
